NewzResearchers at the Vall d'Hebron Institute in Barcelona have identified that the presence of the bacterium 'Fusobacterium' in the stool of patients who have undergone surgery for colorectal cancer can serve as a biomarker for potential recurrence. According to initial study results, this detection method allows clinicians to anticipate a relapse up to three years before it clinically manifests.
This finding offers a potential diagnostic tool for monitoring post-surgical patients. By identifying the bacteria early, medical teams may be able to detect signs of cancer returning well in advance of traditional diagnostic methods, providing a significant window for intervention.
In-depth summary · AI, neutral